Stockreport

Nkarta: NK Cell Therapy Advancement On Two Fronts [Seeking Alpha]

Nkarta, Inc.  (NKTX) 
PDF The global non-Hodgkin's Lymphoma market is expected to reach $20 billion by the end of 2036. NKX019 is also being used to target patients with autoimmune disorders l [Read more]